Sirolimus for the treatment of complicated vascular anomalies in children

Pediatr Blood Cancer. 2011 Dec 1;57(6):1018-24. doi: 10.1002/pbc.23124. Epub 2011 Mar 28.


Background: Vascular anomalies comprise a diverse group of diagnoses. While infantile hemangiomas are common, the majority of these conditions are quite rare and have not been widely studied. Some of these lesions, though benign, can impair vital structures, be deforming, or even become life-threatening. Vascular tumors such as kaposiform hemangioendotheliomas (KHE) and complicated vascular malformations have proven particularly difficult to treat.

Procedure: Here we retrospectively evaluate a series of six patients with complicated, life-threatening vascular anomalies who were treated with the mTOR inhibitor sirolimus for compassionate use at two centers after failing multiple other therapies.

Results: These patients showed significant improvement in clinical status with tolerable side effects.

Conclusions: Sirolimus appears to be effective and safe in patients with life-threatening vascular anomalies and represents an important tool in treating these diseases. These findings are currently being further evaluated in a Phase II safety and efficacy trial.

MeSH terms

  • Adolescent
  • Child
  • Child, Preschool
  • Compassionate Use Trials
  • Female
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Immunosuppressive Agents / therapeutic use*
  • Infant
  • Male
  • Retrospective Studies
  • Sirolimus / adverse effects
  • Sirolimus / therapeutic use*
  • Treatment Outcome
  • Vascular Malformations / complications*
  • Vascular Malformations / drug therapy*


  • Immunosuppressive Agents
  • Sirolimus